NeuBase Therapeutics Reports Business Update and Financial :

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Jessica Yingling , Toddp Branning , Dietricha Stephan , Lifesci Advisors , Little Dog Communications Inc , Drug Administration , Good Laboratory Practice , Nasdaq , Huntington Disease Hd Program , Neubase Therapeutics Inc , Exchange Commission , Oncology Program , Investigational New Drug , Manufacturing Practice , Chief Financial Officer , Base Therapeutics , Chief Executive Officer , Chief Financial , Fiscal Year , Recent Operating , Dystrophy Type , New Chief Financial Officer , Fiscal Quarter Ended December , Private Securities Litigation Reform , Base Investor Contact , Sci Advisors , Base Media Contact , Nasdaq Nbse , Neubase Therapeutics , Nc ,